| __timestamp | Amgen Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4422000000 | 3243000 |
| Thursday, January 1, 2015 | 4227000000 | 2472000 |
| Friday, January 1, 2016 | 4162000000 | 2548000 |
| Sunday, January 1, 2017 | 4069000000 | 19623000 |
| Monday, January 1, 2018 | 4101000000 | 30421000 |
| Tuesday, January 1, 2019 | 4356000000 | 32793999 |
| Wednesday, January 1, 2020 | 6159000000 | 28304000 |
| Friday, January 1, 2021 | 6454000000 | 620000 |
| Saturday, January 1, 2022 | 6406000000 | 755000 |
| Sunday, January 1, 2023 | 8415000000 | 1322000 |
| Monday, January 1, 2024 | 12858000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, cost efficiency is a critical metric for success. This analysis delves into the cost of revenue trends for Amgen Inc. and Viridian Therapeutics, Inc. over the past decade. Amgen, a biotech giant, consistently reported a cost of revenue averaging around $5.3 billion annually, with a notable increase of 30% from 2020 to 2023. In contrast, Viridian, a smaller player, exhibited a more volatile pattern, with costs peaking in 2019 at $32.8 million before dropping significantly in subsequent years. This stark difference highlights the scale and operational efficiency of Amgen compared to the nimble, yet fluctuating, financial strategies of Viridian. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into the strategic maneuvers of both established and emerging pharmaceutical companies.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Amgen Inc.
Cost of Revenue Comparison: Amgen Inc. vs Walgreens Boots Alliance, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue: Key Insights for GSK plc and Viridian Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Viridian Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.